Maravai LifeSciences Holdings, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect three nominees to the Board of Directors (3-year term expiring in 2029): Bernd Brust

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Bernd Brust”): 182,998,545 for, 19,825,453 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 20,186,507 for, 2,739,881 withheld, 39 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To elect three nominees to the Board of Directors (3-year term expiring in 2029): Gregory T. Lucier

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Gregory T. Lucier”): 179,514,826 for, 23,309,172 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 19,576,430 for, 3,349,946 withheld, 51 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To elect three nominees to the Board of Directors (3-year term expiring in 2029): Luke Marker

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Luke Marker”): 182,239,834 for, 20,584,164 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 19,895,439 for, 3,030,946 withheld, 42 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF MARAVAI'S NAMED EXECUTIVE OFFICERS.

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“3. Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting”): 200,054,156 for, 2,457,403 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved, on a non-binding and advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 49 managers: 22,676,570 for, 249,856 against, 1 abstained. Showing the 25 largest; see all in the interactive database.

No total is shown for the institutional-manager reports: their sum exceeds the company's reported shares outstanding. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as Maravai's independent registered public accounting firm for the year ending December 31, 2026.

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“2. Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 234,492,897 for, 1,246,939 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified by the Company's shareholders.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 22,926,426 for, 1 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.